ASTRANA HEALTH INC (ASTH) Fundamental Analysis & Valuation
NASDAQ:ASTH • US03763A2078
Current stock price
23.81 USD
-0.42 (-1.73%)
At close:
23.81 USD
0 (0%)
After Hours:
This ASTH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. ASTH Profitability Analysis
1.1 Basic Checks
- In the past year ASTH was profitable.
- ASTH had a positive operating cash flow in the past year.
- In the past 5 years ASTH has always been profitable.
- ASTH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- ASTH has a Return On Assets of 1.01%. This is comparable to the rest of the industry: ASTH outperforms 51.00% of its industry peers.
- Looking at the Return On Equity, with a value of 2.89%, ASTH is in line with its industry, outperforming 57.00% of the companies in the same industry.
- The Return On Invested Capital of ASTH (3.75%) is comparable to the rest of the industry.
- The Average Return On Invested Capital over the past 3 years for ASTH is below the industry average of 8.86%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.01% | ||
| ROE | 2.89% | ||
| ROIC | 3.75% |
ROA(3y)3.57%
ROA(5y)4.69%
ROE(3y)6.27%
ROE(5y)8.46%
ROIC(3y)5.51%
ROIC(5y)6.5%
1.3 Margins
- ASTH has a Profit Margin (0.71%) which is comparable to the rest of the industry.
- ASTH's Profit Margin has declined in the last couple of years.
- ASTH has a Operating Margin (3.08%) which is comparable to the rest of the industry.
- In the last couple of years the Operating Margin of ASTH has declined.
- The Gross Margin of ASTH (10.73%) is worse than 73.00% of its industry peers.
- In the last couple of years the Gross Margin of ASTH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.08% | ||
| PM (TTM) | 0.71% | ||
| GM | 10.73% |
OM growth 3Y-30.31%
OM growth 5Y-23.43%
PM growth 3Y-43.64%
PM growth 5Y-33.68%
GM growth 3Y-14.93%
GM growth 5Y-13%
2. ASTH Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ASTH is destroying value.
- Compared to 1 year ago, ASTH has more shares outstanding
- The number of shares outstanding for ASTH has been increased compared to 5 years ago.
- ASTH has a worse debt/assets ratio than last year.
2.2 Solvency
- ASTH has an Altman-Z score of 2.41. This is not the best score and indicates that ASTH is in the grey zone with still only limited risk for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 2.41, ASTH is in line with its industry, outperforming 58.00% of the companies in the same industry.
- ASTH has a debt to FCF ratio of 9.94. This is a negative value and a sign of low solvency as ASTH would need 9.94 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 9.94, ASTH is in line with its industry, outperforming 42.00% of the companies in the same industry.
- ASTH has a Debt/Equity ratio of 1.27. This is a high value indicating a heavy dependency on external financing.
- The Debt to Equity ratio of ASTH (1.27) is worse than 64.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.27 | ||
| Debt/FCF | 9.94 | ||
| Altman-Z | 2.41 |
ROIC/WACC0.48
WACC7.74%
2.3 Liquidity
- A Current Ratio of 1.40 indicates that ASTH should not have too much problems paying its short term obligations.
- With a Current ratio value of 1.40, ASTH perfoms like the industry average, outperforming 53.00% of the companies in the same industry.
- A Quick Ratio of 1.40 indicates that ASTH should not have too much problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 1.40, ASTH is in line with its industry, outperforming 59.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.4 |
3. ASTH Growth Analysis
3.1 Past
- ASTH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -48.31%.
- ASTH shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -14.74% yearly.
- ASTH shows a strong growth in Revenue. In the last year, the Revenue has grown by 56.39%.
- The Revenue has been growing by 35.87% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-48.31%
EPS 3Y-24.29%
EPS 5Y-14.74%
EPS Q2Q%180%
Revenue 1Y (TTM)56.39%
Revenue growth 3Y40.62%
Revenue growth 5Y35.87%
Sales Q2Q%42.89%
3.2 Future
- The Earnings Per Share is expected to grow by 54.34% on average over the next years. This is a very strong growth
- ASTH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.59% yearly.
EPS Next Y174.35%
EPS Next 2Y103.85%
EPS Next 3Y87.86%
EPS Next 5Y54.34%
Revenue Next Year25.65%
Revenue Next 2Y18.01%
Revenue Next 3Y13.68%
Revenue Next 5Y9.59%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. ASTH Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 51.76, the valuation of ASTH can be described as expensive.
- ASTH's Price/Earnings ratio is in line with the industry average.
- When comparing the Price/Earnings ratio of ASTH to the average of the S&P500 Index (25.23), we can say ASTH is valued expensively.
- A Price/Forward Earnings ratio of 18.87 indicates a rather expensive valuation of ASTH.
- ASTH's Price/Forward Earnings ratio is in line with the industry average.
- Compared to an average S&P500 Price/Forward Earnings ratio of 22.42, ASTH is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 51.76 | ||
| Fwd PE | 18.87 |
4.2 Price Multiples
- ASTH's Enterprise Value to EBITDA ratio is in line with the industry average.
- Based on the Price/Free Cash Flow ratio, ASTH is valued a bit cheaper than 79.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.27 | ||
| EV/EBITDA | 12.56 |
4.3 Compensation for Growth
- ASTH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- ASTH's earnings are expected to grow with 87.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.3
PEG (5Y)N/A
EPS Next 2Y103.85%
EPS Next 3Y87.86%
5. ASTH Dividend Analysis
5.1 Amount
- ASTH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ASTH Fundamentals: All Metrics, Ratios and Statistics
23.81
-0.42 (-1.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-02 2026-03-02/bmo
Earnings (Next)05-06 2026-05-06
Inst Owners59.72%
Inst Owner ChangeN/A
Ins Owners9.87%
Ins Owner Change0.91%
Market Cap1.18B
Revenue(TTM)3.18B
Net Income(TTM)22.49M
Analysts84.71
Price Target36.38 (52.79%)
Short Float %7.49%
Short Ratio5.13
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP35.06%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-43.4%
Min EPS beat(2)-97.78%
Max EPS beat(2)10.99%
EPS beat(4)1
Avg EPS beat(4)-44.97%
Min EPS beat(4)-97.78%
Max EPS beat(4)10.99%
EPS beat(8)4
Avg EPS beat(8)-50.25%
EPS beat(12)7
Avg EPS beat(12)-23.47%
EPS beat(16)10
Avg EPS beat(16)-9.93%
Revenue beat(2)1
Avg Revenue beat(2)-0.74%
Min Revenue beat(2)-1.62%
Max Revenue beat(2)0.15%
Revenue beat(4)2
Avg Revenue beat(4)-1.11%
Min Revenue beat(4)-3.56%
Max Revenue beat(4)0.57%
Revenue beat(8)5
Avg Revenue beat(8)0.83%
Revenue beat(12)7
Avg Revenue beat(12)0.78%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.13%
PT rev (3m)-11.39%
EPS NQ rev (1m)29.91%
EPS NQ rev (3m)29.91%
EPS NY rev (1m)-1.02%
EPS NY rev (3m)-8.28%
Revenue NQ rev (1m)0.19%
Revenue NQ rev (3m)0.19%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)0.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 51.76 | ||
| Fwd PE | 18.87 | ||
| P/S | 0.37 | ||
| P/FCF | 11.27 | ||
| P/OCF | 10.28 | ||
| P/B | 1.51 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.56 |
EPS(TTM)0.46
EY1.93%
EPS(NY)1.26
Fwd EY5.3%
FCF(TTM)2.11
FCFY8.87%
OCF(TTM)2.32
OCFY9.73%
SpS64.32
BVpS15.75
TBVpS-7.22
PEG (NY)0.3
PEG (5Y)N/A
Graham Number12.77
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.01% | ||
| ROE | 2.89% | ||
| ROCE | 6.12% | ||
| ROIC | 3.75% | ||
| ROICexc | 5.12% | ||
| ROICexgc | 160.26% | ||
| OM | 3.08% | ||
| PM (TTM) | 0.71% | ||
| GM | 10.73% | ||
| FCFM | 3.28% |
ROA(3y)3.57%
ROA(5y)4.69%
ROE(3y)6.27%
ROE(5y)8.46%
ROIC(3y)5.51%
ROIC(5y)6.5%
ROICexc(3y)8.45%
ROICexc(5y)10.18%
ROICexgc(3y)90.21%
ROICexgc(5y)71.8%
ROCE(3y)9%
ROCE(5y)10.61%
ROICexgc growth 3Y64.68%
ROICexgc growth 5Y30.22%
ROICexc growth 3Y-25.1%
ROICexc growth 5Y-14.45%
OM growth 3Y-30.31%
OM growth 5Y-23.43%
PM growth 3Y-43.64%
PM growth 5Y-33.68%
GM growth 3Y-14.93%
GM growth 5Y-13%
F-Score4
Asset Turnover1.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.27 | ||
| Debt/FCF | 9.94 | ||
| Debt/EBITDA | 6.89 | ||
| Cap/Depr | 22.09% | ||
| Cap/Sales | 0.32% | ||
| Interest Coverage | 2.14 | ||
| Cash Conversion | 79.65% | ||
| Profit Quality | 464.67% | ||
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.4 | ||
| Altman-Z | 2.41 |
F-Score4
WACC7.74%
ROIC/WACC0.48
Cap/Depr(3y)70.53%
Cap/Depr(5y)90.42%
Cap/Sales(3y)0.92%
Cap/Sales(5y)1.45%
Profit Quality(3y)210.81%
Profit Quality(5y)167.52%
High Growth Momentum
Growth
EPS 1Y (TTM)-48.31%
EPS 3Y-24.29%
EPS 5Y-14.74%
EPS Q2Q%180%
EPS Next Y174.35%
EPS Next 2Y103.85%
EPS Next 3Y87.86%
EPS Next 5Y54.34%
Revenue 1Y (TTM)56.39%
Revenue growth 3Y40.62%
Revenue growth 5Y35.87%
Sales Q2Q%42.89%
Revenue Next Year25.65%
Revenue Next 2Y18.01%
Revenue Next 3Y13.68%
Revenue Next 5Y9.59%
EBIT growth 1Y9.82%
EBIT growth 3Y-2%
EBIT growth 5Y4.04%
EBIT Next Year220.54%
EBIT Next 3Y60.15%
EBIT Next 5Y39.29%
FCF growth 1Y136.58%
FCF growth 3Y20.86%
FCF growth 5Y18.35%
OCF growth 1Y119.54%
OCF growth 3Y11.74%
OCF growth 5Y19.94%
ASTRANA HEALTH INC / ASTH Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for ASTRANA HEALTH INC?
ChartMill assigns a fundamental rating of 4 / 10 to ASTH.
What is the valuation status of ASTRANA HEALTH INC (ASTH) stock?
ChartMill assigns a valuation rating of 4 / 10 to ASTRANA HEALTH INC (ASTH). This can be considered as Fairly Valued.
How profitable is ASTRANA HEALTH INC (ASTH) stock?
ASTRANA HEALTH INC (ASTH) has a profitability rating of 3 / 10.
What is the valuation of ASTRANA HEALTH INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ASTRANA HEALTH INC (ASTH) is 51.76 and the Price/Book (PB) ratio is 1.51.
Can you provide the financial health for ASTH stock?
The financial health rating of ASTRANA HEALTH INC (ASTH) is 3 / 10.